CL2020002604A1 - Ciertos compuestos de pladienolida y métodos de uso. - Google Patents
Ciertos compuestos de pladienolida y métodos de uso.Info
- Publication number
- CL2020002604A1 CL2020002604A1 CL2020002604A CL2020002604A CL2020002604A1 CL 2020002604 A1 CL2020002604 A1 CL 2020002604A1 CL 2020002604 A CL2020002604 A CL 2020002604A CL 2020002604 A CL2020002604 A CL 2020002604A CL 2020002604 A1 CL2020002604 A1 CL 2020002604A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- methods
- useful
- certain
- pladienolide compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 238000011374 additional therapy Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000001324 spliceosome Anatomy 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente divulgación proporciona compuestos de pladienolida novedosos, composiciones farmacéuticas que contienen dichos compuestos, y métodos para usar los compuestos como agentes terapéuticos. Estos compuestos pueden ser útiles en el tratamiento de cánceres, particularmente cánceres en los que se sabe que son útiles los agentes que se dirigen al espliceosoma y las mutaciones en el mismo. También se proporcionan en el presente documento métodos para tratar cánceres mediante la administración de al menos un compuesto divulgado en el presente documento y al menos una terapia adicional.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862655021P | 2018-04-09 | 2018-04-09 | |
US201862679653P | 2018-06-01 | 2018-06-01 | |
US201962814843P | 2019-03-06 | 2019-03-06 | |
US201962814838P | 2019-03-06 | 2019-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002604A1 true CL2020002604A1 (es) | 2021-01-15 |
Family
ID=66248768
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002604A CL2020002604A1 (es) | 2018-04-09 | 2020-10-08 | Ciertos compuestos de pladienolida y métodos de uso. |
CL2022000458A CL2022000458A1 (es) | 2018-04-09 | 2022-02-24 | Ciertos compuestos de pladienolida y métodos de uso. (divisional de solicitud 202002604) |
CL2023002549A CL2023002549A1 (es) | 2018-04-09 | 2023-08-29 | Ciertos compuestos de pladienolida y métodos de uso (divisional). |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022000458A CL2022000458A1 (es) | 2018-04-09 | 2022-02-24 | Ciertos compuestos de pladienolida y métodos de uso. (divisional de solicitud 202002604) |
CL2023002549A CL2023002549A1 (es) | 2018-04-09 | 2023-08-29 | Ciertos compuestos de pladienolida y métodos de uso (divisional). |
Country Status (18)
Country | Link |
---|---|
US (1) | US11926619B2 (es) |
EP (1) | EP3774759A2 (es) |
JP (2) | JP7335265B2 (es) |
KR (1) | KR20210006907A (es) |
CN (1) | CN113166091A (es) |
AU (2) | AU2019251096B2 (es) |
BR (1) | BR112020020792A2 (es) |
CA (1) | CA3096400A1 (es) |
CL (3) | CL2020002604A1 (es) |
CO (1) | CO2020013834A2 (es) |
IL (2) | IL303335A (es) |
JO (2) | JOP20200243A1 (es) |
MX (3) | MX2020010606A (es) |
PE (1) | PE20212327A1 (es) |
PH (1) | PH12020500666A1 (es) |
SG (1) | SG11202009906TA (es) |
TW (1) | TW201945351A (es) |
WO (1) | WO2019199667A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202233187A (zh) | 2020-11-04 | 2022-09-01 | 日商衛材R&D企管股份有限公司 | 骨髓發育不良症候群(mds)之生物標記物及其使用方法 |
WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
CN115414351B (zh) * | 2022-09-19 | 2024-05-17 | 山东大学齐鲁医院 | pladienolide B与PD-L1抗体组合在肿瘤免疫治疗领域的应用 |
WO2024101298A1 (ja) * | 2022-11-07 | 2024-05-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | マクロライド化合物の製造方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
WO1997017614A1 (en) | 1995-11-10 | 1997-05-15 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
TWI312681B (en) * | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
JP4459051B2 (ja) | 2002-07-31 | 2010-04-28 | メルシャン株式会社 | 新規生理活性物質 |
RU2338741C2 (ru) | 2002-07-31 | 2008-11-20 | Мершан Корпорейшн | Новые физиологически активные вещества |
WO2004037212A2 (en) | 2002-10-24 | 2004-05-06 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
BR0316746A (pt) | 2002-11-29 | 2005-10-18 | Mercian Corp | Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550) |
KR20060110865A (ko) | 2003-11-27 | 2006-10-25 | 에자이 가부시키가이샤 | 매크로라이드계 화합물의 수산화에 관여하는 dna |
ES2343843T3 (es) * | 2004-02-06 | 2010-08-11 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento para examinar la sensibilidad de celulas cancerosas a un agente anticanceroso. |
KR100834488B1 (ko) | 2004-07-20 | 2008-06-09 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 플라디에놀라이드의 생합성에 관여하는 폴리펩티드를코딩하는 dna |
WO2007110704A2 (en) * | 2005-09-28 | 2007-10-04 | Novimmune Sa | Macrolide compositions as therapeutic agent |
WO2007110705A2 (en) | 2005-09-28 | 2007-10-04 | Novimmune Sa | Macrolide as inhibitors of mhc class ii |
EP1935893A4 (en) | 2005-10-13 | 2009-07-22 | Eisai R&D Man Co Ltd | TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D |
EP2052723A4 (en) | 2006-08-14 | 2010-07-28 | Eisai R&D Man Co Ltd | STABLE LYOPHILIZED PREPARATION |
MX2009008068A (es) | 2007-01-29 | 2009-11-18 | Eisai R&D Man Co Ltd | Compuesto macrolido en forma solida, proceso para su preparacion y composicion farmaceutica que lo contiene. |
US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
EP2168961A1 (en) * | 2007-07-06 | 2010-03-31 | Eisai R&D Management Co., Ltd. | Process for producing macrolide compound and intermediate therefor |
WO2013148324A1 (en) * | 2012-03-26 | 2013-10-03 | The Regents Of The University Of California | Anti-cancer polyketide compounds |
US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
US20140275010A1 (en) * | 2013-03-12 | 2014-09-18 | Guo Zhu Zheng | Quaternary salts |
UA119458C2 (uk) * | 2014-05-15 | 2019-06-25 | Ейсей Р Енд Д Менеджмент Ко., Лтд. | Сполуки піридину пладієноліду та способи застосування |
DK3309174T3 (da) | 2014-07-11 | 2022-06-07 | Ventana Med Syst Inc | ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf |
EP3344780B1 (en) | 2015-09-01 | 2021-06-23 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
CN108473479B (zh) * | 2015-11-18 | 2024-05-07 | 卫材研究发展管理有限公司 | 普拉二烯内酯吡啶化合物的固态形式和使用方法 |
CA3101205A1 (en) | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
-
2019
- 2019-04-08 IL IL303335A patent/IL303335A/en unknown
- 2019-04-08 MX MX2020010606A patent/MX2020010606A/es unknown
- 2019-04-08 AU AU2019251096A patent/AU2019251096B2/en active Active
- 2019-04-08 JP JP2020555130A patent/JP7335265B2/ja active Active
- 2019-04-08 JO JOP/2020/0243A patent/JOP20200243A1/ar unknown
- 2019-04-08 CA CA3096400A patent/CA3096400A1/en active Pending
- 2019-04-08 PE PE2020001558A patent/PE20212327A1/es unknown
- 2019-04-08 US US17/045,952 patent/US11926619B2/en active Active
- 2019-04-08 CN CN201980039253.0A patent/CN113166091A/zh active Pending
- 2019-04-08 EP EP19719036.6A patent/EP3774759A2/en active Pending
- 2019-04-08 KR KR1020207032258A patent/KR20210006907A/ko not_active Application Discontinuation
- 2019-04-08 JO JOP/2020/0242A patent/JOP20200242A1/ar unknown
- 2019-04-08 TW TW108112206A patent/TW201945351A/zh unknown
- 2019-04-08 WO PCT/US2019/026313 patent/WO2019199667A2/en unknown
- 2019-04-08 BR BR112020020792-6A patent/BR112020020792A2/pt unknown
- 2019-04-08 IL IL277749A patent/IL277749B2/en unknown
- 2019-04-08 SG SG11202009906TA patent/SG11202009906TA/en unknown
-
2020
- 2020-10-08 MX MX2022015216A patent/MX2022015216A/es unknown
- 2020-10-08 MX MX2023009976A patent/MX2023009976A/es unknown
- 2020-10-08 CL CL2020002604A patent/CL2020002604A1/es unknown
- 2020-10-08 PH PH12020500666A patent/PH12020500666A1/en unknown
- 2020-11-05 CO CONC2020/0013834A patent/CO2020013834A2/es unknown
-
2022
- 2022-02-24 CL CL2022000458A patent/CL2022000458A1/es unknown
-
2023
- 2023-04-18 AU AU2023202358A patent/AU2023202358A1/en active Pending
- 2023-08-17 JP JP2023132865A patent/JP2023156456A/ja active Pending
- 2023-08-29 CL CL2023002549A patent/CL2023002549A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2023009976A (es) | 2023-10-30 |
IL277749A (en) | 2020-11-30 |
WO2019199667A3 (en) | 2019-11-21 |
IL303335A (en) | 2023-07-01 |
AU2019251096A1 (en) | 2020-11-26 |
IL277749B1 (en) | 2023-07-01 |
JOP20200243A1 (ar) | 2020-09-29 |
AU2023202358A1 (en) | 2023-05-18 |
JOP20200242A1 (ar) | 2020-09-29 |
JP7335265B2 (ja) | 2023-08-29 |
SG11202009906TA (en) | 2020-11-27 |
CO2020013834A2 (es) | 2020-12-10 |
KR20210006907A (ko) | 2021-01-19 |
AU2019251096B2 (en) | 2023-04-20 |
US11926619B2 (en) | 2024-03-12 |
CA3096400A1 (en) | 2019-10-17 |
TW201945351A (zh) | 2019-12-01 |
US20210163456A1 (en) | 2021-06-03 |
PH12020500666A1 (en) | 2021-07-26 |
CN113166091A (zh) | 2021-07-23 |
WO2019199667A2 (en) | 2019-10-17 |
IL277749B2 (en) | 2023-11-01 |
BR112020020792A2 (pt) | 2021-01-12 |
EP3774759A2 (en) | 2021-02-17 |
CL2022000458A1 (es) | 2022-10-21 |
JP2021521124A (ja) | 2021-08-26 |
MX2022015216A (es) | 2023-01-04 |
CL2023002549A1 (es) | 2024-01-26 |
JP2023156456A (ja) | 2023-10-24 |
PE20212327A1 (es) | 2021-12-14 |
MX2020010606A (es) | 2021-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002604A1 (es) | Ciertos compuestos de pladienolida y métodos de uso. | |
CO2022010241A2 (es) | Inhibidores de sos1 | |
CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
CY1122984T1 (el) | Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους | |
CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
CL2020002605A1 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer. | |
PE20191474A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer | |
EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
PE20171241A1 (es) | Terapias de combinacion para el tratamiento de canceres | |
AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
CR20190361A (es) | Dendrímeros terapéuticos | |
EA202192905A1 (ru) | Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли | |
CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
CL2020000127A1 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa. | |
AR117459A1 (es) | Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos | |
AR126389A1 (es) | Compuestos tricíclicos como inhibidores de kras | |
CO2019001967A2 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores |